ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-13 12:00 |
Abivax does not hold any cash or otherwise have any deposits at SVB or at any o…
|
English | 6.9 KB | ||
| 2023-03-01 09:13 |
Franchissement de seuils
|
French | 200.4 KB | ||
| 2023-02-27 17:45 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.0 KB | ||
| 2023-02-23 20:00 |
Abivax annonce la mise à disposition d’un prospectus dans le cadre de son augme…
|
French | 137.3 KB | ||
| 2023-02-23 20:00 |
Abivax publishes a prospectus in the context of its capital increase
|
English | 9.7 KB | ||
| 2023-02-22 18:05 |
Abivax annonce le succès d’un financement cross-over sursouscrit de 130 million…
|
French | 541.3 KB | ||
| 2023-02-22 18:05 |
Abivax announces successful oversubscribed EUR 130M cross-over financing at mar…
|
English | 76.1 KB | ||
| 2023-02-17 08:00 |
Abivax: Le Dr. Sheldon Sloan, M.D., est nommé Directeur Médical d’Abivax
|
French | 197.5 KB | ||
| 2023-02-17 08:00 |
Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
|
English | 14.2 KB | ||
| 2023-02-14 18:00 |
Abivax présentera lors du 18ème Congrès de l’ECCO des données issues d’échantil…
|
French | 232.1 KB | ||
| 2023-02-14 18:00 |
Abivax to present blood and rectal tissue data from UC patients treated with ob…
|
English | 13.8 KB | ||
| 2023-01-31 18:00 |
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND…
|
English | 167.4 KB | ||
| 2023-01-31 18:00 |
ABIVAX: AVIS AUX PORTEURS D’OBLIGATIONS CONVERTIBLES/ECHANGEABLES EN ACTIONS NO…
|
French | 156.0 KB | ||
| 2023-01-30 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.1 KB | ||
| 2023-01-30 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 31 décembre 2022
|
French | 325.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
